1. Home
  2. NGNE vs DGICA Comparison

NGNE vs DGICA Comparison

Compare NGNE & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$30.98

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

DGICA

Donegal Group Inc.

HOLD

Current Price

$18.21

Market Cap

714.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
DGICA
Founded
2003
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
714.2M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
NGNE
DGICA
Price
$30.98
$18.21
Analyst Decision
Strong Buy
Hold
Analyst Count
7
1
Target Price
$63.57
$19.00
AVG Volume (30 Days)
234.1K
87.4K
Earning Date
05-08-2026
04-30-2026
Dividend Yield
N/A
4.14%
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
$978,014,322.00
Revenue This Year
N/A
$2.26
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.82
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$16.11
52 Week High
$43.66
$21.06

Technical Indicators

Market Signals
Indicator
NGNE
DGICA
Relative Strength Index (RSI) 41.25 N/A
Support Level $31.20 N/A
Resistance Level $33.99 N/A
Average True Range (ATR) 1.95 0.00
MACD -0.47 0.00
Stochastic Oscillator 20.29 0.00

Price Performance

Historical Comparison
NGNE
DGICA

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About DGICA Donegal Group Inc.

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

Share on Social Networks: